Skip directly to site content
Are You Still There?
Due to inactivity, you will be signed out in two minutes unless you click 'Continue'.

Are you still there?

Due to inactivity, you will be signed out in two minutes unless
you click 'Continue'.

Panel:   Aminoglycoside/tetracycline Resistance (ATR)
AR Bank # 0578 Enterococcus faecium
Study ID: ATR-38

Biosample Accession #: SAMN11954010

MLST: 80(Pasteur)

MICs obtained by broth microdilution. Modal MIC is reported.

MIC results for each antimicrobial agent for an isolate may commonly be ± 1 log2 (doubling dilution) different than what is posted on the FDA & CDC AR Bank website because this is the normal technical variability of antimicrobial susceptibility testing (see J. H. Jorgensen. 1993. J Clin Microbiol. Vol 31[11]: 2841-2844).

Panel:  Aminoglycoside/tetracycline Resistance (ATR)  |  Aminoglycoside/tetracycline Resistance - Gram positive set (ATR-GP) (Custom)

MIC (μg/ml) Results and Interpretation
Drug MIC (μg/ml) INT
Ampicillin >128R
Chloramphenicol 16I
Daptomycin 8R
Doxycycline 16R
Eravacycline 20.03S
High-Level Gentamicin >500SYN-R
High-Level Streptomycin 3<=1000SYN-S
Levofloxacin >8R
Linezolid 2S
Penicillin >256R
Quinupristin/dalfopristin 11S
Rifampin >4R
Teicoplanin 2S
Vancomycin 0.5S
S – I –R Interpretation (INT) derived from CLSI 2020 M100 S30
SDD (Susceptible Dose Dependent)

1 Reflects MIC of first component
2 Based on FDA break points
3 Synergy of aminoglycosides and cell-wall agents (i.e., penicillin, ampicillin, or vancomycin) is possible only if both are susceptible
Device manufacturers and users of FDA cleared devices shall consult the FDA’s Antibacterial Susceptibility Test Interpretive Criteria       website for breakpoints recognized or recommended by FDA, and for information regarding FDA exceptions or additions to the applicable, recognized consensus standard.
Molecular Mechanisms of Resistance
Aminoglycoside aac(6')-Ie, aacA-ENT1
Macrolide-Lincosamide-Streptogramin erm(T)
Tetracyclines tet(M)
Trimethoprim dfrG
AR gene prediction was performed using ARG-ANNOT and ResFinder databases accessed on 20180608. AR drug classes are assigned according to these databases. This analysis does not include mutations that may result in antibiotic resistance or resistance determinants added to newer versions of used database or other antimicrobial resistance gene databases. For resistance determinant detection, 99-100% sequence identity and 100% sequence coverage from GAMMA and SRST2 was used. GAMMA uses amino acid sequence to assign gene alleles from assemblies; SRST2 uses nucleotide sequence to assign gene alleles from sequencing reads. Biosample accession numbers have been provided so that users can analyze the data on their own if so desired. *MLST Type (and scheme), as determined by Torsten Seemann's MLST program. For Enterobacteriaceae, the Pasteur MLST schemes are used except for E. coli for which both the Pasteur and Achtman schemes are reported. SUB=novel MLST identified and "submitted". **Presence of Efflux Pump may not be associated with resistance.
Medium: Trypticase Soy Agar with 5% Sheep Blood (BAP)

Temperature: 35°C
Atmosphere: Aerobic


Remove the sample vial to a container with dry ice or a freezer block. Keep vial on ice or block. (Do not let vial content thaw)

Open vial aseptically to avoid contamination

Using a sterile loop, remove a small amount of frozen isolate from the top of the vial

Aseptically transfer the loop to BAP

Use streak plate method to isolate single colonies

Incubate inverted plate at 35°C ± 2°C for 18-24 hrs.

Storage Temperature & Biosafety

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the current publication of 'BioSafety in Microbiological and Biomedical Laboratories' from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and National Institutes of Health.

This product is sent with the condition that you are responsible for its safe storage, handling, and use. All materials are the property of the Centers for Disease Control and Prevention (CDC) and have been made available on behalf of the Food and Drug Administration (FDA). This material is not for use in human subjects and may not be redistributed. While CDC uses reasonable efforts to include accurate and up-to-date information on this product sheet, CDC makes no warranties or representations as to its accuracy. CDC is not liable for damages arising from the misidentification or misrepresentation of cultures. Please refer to the Standard Letter Agreement (SLA) for further details regarding the use of this product.
Isolate History
Date Action Performed
08/22/23INT was updated with a new value for Quinupristin/dalfopristin: from 'R' to 'S'
03/09/23MIC was updated with a new value for Eravacycline: from '0.06' to '0.03'
11/07/22MLST was updated
09/19/22Gene was added
09/19/22Category was added
09/19/22Gene was removed
Top of Page